ASXC has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ASXC has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Asensus Surgical has the Growth Rank of 2.
GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:
1. 5-year revenue growth rate, the higher, the better.GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.
Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.
For the Medical Devices subindustry, Asensus Surgical's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Asensus Surgical's Growth Rank distribution charts can be found below:
* The bar in red indicates where Asensus Surgical's Growth Rank falls into.
Thank you for viewing the detailed overview of Asensus Surgical's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.
Starling William N Jr | director | 2300 BUCKSKIN ROAD, POCATELLO ID 83201 |
Andrea Biffi | director | C/O SOFAR SPA, VIA FIRENZE 40, TREZZANO ROSA (MI) L6 20060 |
Elizabeth Kwo | director | C/O FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON MA 01803 |
David Bruce Milne | director | ONE BOSTON PLACE, 201 WASHINGTON STREET, SUITE 3900, BOSTON MA 02108 |
Kevin J Hobert | director | 343 STATE STREET, ROCHESTER NY 14650 |
Fernando Anthony C. J. | officer: Chief Technology Officer | 635 DAVIS DRIVE, SUITE 300, MORRISVILLE NC 27560 |
Rampertab Shameze | officer: EVP, Chief Financial Officer | C/O ZOMEDICA PHARMACEUTICALS CORP., 3928 VARSITY DRIVE, ANN ARBOR MI 48108 |
Brett Farabaugh | officer: Interim CFO | 108 T.W. ALEXANDER DRIVE, RESEARCH TRIANGLE PARK NC 27709 |
Joseph P Slattery | officer: EVP and CFO | C/O TRANSENTERIX, INC., 635 DAVIS DRIVE, SUITE 300, MORRISVILLE NC 27560 |
Eric A Smith | officer: Chief Commercial Officer | 7 CALEB CIRCLE, SAN ANTONIO TX 78258 |
Todd Pope | director, officer: President and CEO | C/O TRANSENTERIX, 635 DAVIS DRIVE, SUITE 300, MORRISVILLE NC 27713 |
Willam N Kelley | director | MERCK & CO., INC., ONE MERCK DRIVE, WHITEHOUSE STATION X1 08889 |
Pfenniger Richard C Jr | director | 4400 BISCAYNE BLVD., MIAMI FL 33137 |
Sofar, S.p.a | 10 percent owner | VIA FIRENZE 40, TREZZANO ROSA L6 20060 |
Andrew N Schiff | director, 10 percent owner | PLANET ZANETT INC, 135 E 57TH ST, NEW YORK NY 10022 |
From GuruFocus
By Marketwired Marketwired • 04-17-2019
By Barry Cohen Barry Cohen • 12-23-2020
By PRNewswire PRNewswire • 05-27-2021
By GuruFocusNews GuruFocusNews • 07-08-2022
By GuruFocusNews GuruFocusNews • 06-28-2022
By PRNewswire PRNewswire • 01-05-2021
By PRNewswire PRNewswire • 03-19-2019
By GF Value • 06-22-2021
By PRNewswire PRNewswire • 01-11-2021
By GF Value GF Value • 05-16-2021
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.